In Paris, Prof. Jonathan Rabinowitz, of Bar-Ilan University’s Louis and Gabi Weisfeld School of Social Work, has addressed the annual meeting of the European College of Neuropsychopharmacology on findings from the NEWMEDS Program in which he is participating.
NEWMEDS (New Medications in Depression and Schizophrenia) is an international consortium of scientists and pharmaceutical leaders formed to develop effective drugs for the treatment of schizophrenia and depression.
Funded by the European Union’s Innovative Medicines Initiative (IMI), NEWMEDS is the largest collaboration of its kind ever assembled. Prof. Rabinowitz heads the Working Group on Advanced Data Analysis Techniques.
A detailed report of the findings presented by Prof. Rabinowitz was published by Clinical Psychiatry News in print and on video. The article and video clip may be viewed here.